Atheronova (PK) Stock Price - AHROQ

Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
Ultimate Trader (Monthly)
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Atheronova Inc (PK) AHROQ OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 0.0015 0.00 0.00 0.00 0.0015 16:18:36
Bid Price Ask Price Spread Spread % News
0.0001 0.256 0.2559 99.96% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Atheronova (PK) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 13.21k 8.81M $ -7.81M - - 5.42M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
314.00 $ - 0.00% - -

more financials information »

Atheronova (PK) News

Loading Messages....

Latest AHROQ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AHROQ Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.00150.00150.00150.00152000.000.0%
1 Month0.00250.00340.00150.002231613,290-0.001-40.0%
3 Months0.00590.0070.00150.004496318,164-0.0044-74.58%
6 Months0.0030.0070.00050.004358715,205-0.0015-50.0%
1 Year0.00160.0080.00050.004088613,521-0.0001-6.25%
3 Years0.0090.05830.00050.015913733,367-0.0075-83.33%
5 Years0.2410.3550.00050.033283651,834-0.2395-99.38%

Atheronova (PK) Description

AtheroNova Inc. is a clinical stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. Atherosclerotic plaque, which progressively narrows and blocks arteries, is the main underlying pathology of cardiovascular disease and the leading killer in industrialized nations worldwide. The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention. Key Investment Considerations $41+ Billion market potential Strong IP protection Identifiable milestones Potentially lower risk of safety or efficacy problems than is typical in drug development Strong management team with successful track record Capital structure

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.